19 results about "Glucose utilization" patented technology

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The present invention relates to the field of pharmaceuticals and health food technology, and specifically to a method for preparing and applying red date polysaccharides. The specific technical solution comprises the following steps: a method for preparing red date polysaccharides comprises concentrating jujubes with distilled water, removing proteins, and then precipitating with ethanol to obtain a primary ethanol precipitate containing polysaccharides; dialyzing the primary ethanol precipitate, and then precipitating with ethanol to obtain a secondary ethanol precipitate containing polysaccharides, which is then freeze-dried. The extracted red date polysaccharides can improve glucose utilization, increase GLUT4 protein expression, and prevent palmitate-induced insulin resistance and muscle damage in muscle cells, and can be used to prevent, improve, or treat anabolic or muscular diseases.

The invention discloses a method for improving clostridium anaerobic fermentation hydrogen volume yield and hydrogen production rate and application. According to the method, biochar is added into a dark fermentation culture medium for anaerobic fermentation to obtain hydrogen. According to the method, the clostridium can be adsorbed on the surface and inside the biochar, so that the clostridium is prevented from being directly contacted with a high-concentration glucose-containing culture medium to a certain extent, the inhibition effect of high-concentration glucose is reduced, and the hydrogen production rate and the glucose utilization rate are increased. Moreover, the biochar is alkaline after being dissolved in water, so that the rapid reduction of the pH of the culture system can be relieved. Meanwhile, the porosity of the biochar is also developed, and the biochar can adsorb part of organic acids such as acetic acid and butyric acid generated by glucose metabolism, so that the inhibition effect of the organic acids on hydrogen production is relieved, and the hydrogen production rate and the glucose utilization rate are further improved. In addition, the method also has the characteristics of low cost, simplicity and convenience in operation and the like, and large-scale industrial application is easy to realize.

The invention provides an engineering strain for synthesizing isoleucine by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second set of polynucleotides comprising at least one polynucleotide encoding an L-isoleucine synthesis pathway enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the first group of polynucleotides, not only is the glucose utilization rate of the engineering strain improved, but also the yield of the L-isoleucine is improved; meanwhile, by overexpressing or strengthening a plurality of L-isoleucine biosynthetic pathway related genes from different sources and knocking out or weakening L-isoleucine degradation pathway related genes, efficient fermentation production of the L-isoleucine is realized.

The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transporter (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds in the treatment of cardiovascular diseases, disorders of fatty acid metabolism and glucose utilization, gastrointestinal diseases and liver diseases.

The invention discloses marine red yeast for efficiently co-producing astaxanthin, carotenoid and ergosterol as well as a co-production process and application of the marine red yeast. According to the invention, a brand new marine rhodotorula mucilaginosa HY-25 is screened and identified, a culture process of the marine rhodotorula mucilaginosa HY-25 is provided, and a process for co-producing astaxanthin, carotenoid and ergosterol through fermentation of the strain is provided. By adopting the fermentation process disclosed by the invention, the amounts of the carotenoid, the astaxanthin and the ergosterol which are co-produced respectively reach 25.45 mg / L, 1.32 mg / L and 55.43 mg / L. Meanwhile, xylose and glucose in the bamboo hydrolysate can be utilized by the strain, the utilization rate of the glucose reaches 90% or above, and the utilization rate of the xylose reaches 30% or above; the strain can adapt to different salt environments, so that the strain can be fermented in sugar-containing wastewater liquid, and high-added-value products are produced by utilizing effective components in the wastewater.

The invention provides an engineering strain for synthesizing homoserine by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second set of polynucleotides comprising at least one polynucleotide encoding an L-homoserine synthesis pathway enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the first group of polynucleotides, not only is the glucose utilization rate of the engineering strain improved, but also the yield of the L-homoserine is improved; meanwhile, by overexpressing or strengthening a plurality of L-homoserine biosynthetic pathway related genes from different sources and knocking out or weakening L-homoserine degradation pathway related genes, efficient fermentation production of the L-homoserine is realized.

The present disclosure provides methods of preventing or treating metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody, optionally in combination with a second agent, are provided, wherein glucose utilization is increased in the periphery and / or the liver, thereby preventing or treating diseases and disorders associated with insulin resistance. Also provided are compositions comprising an anti-CGRP antibody, optionally in combination with a second agent, suitable for administration to increase glucose utilization in the periphery and / or the liver, and thereby prevent or treat diseases and disorders associated with insulin resistance.

The invention discloses application of alpha KG in improving growth performance of ruminant offspring, and belongs to the technical field of feed additives. The alpha KG is used for improving the trans-generation daily gain and the heat production metabolism of the body of the ruminant for the first time, a remarkable and long-acting daily gain trans-generation programming effect is generated on the offspring calves through maternal feeding, the postpartum daily gain of the offspring calves is increased, the BAT development and heat production glycolipid metabolism functions are activated, and the glucose utilization efficiency of the body is optimized in a long-term mode. Experimental results show that after the alpha KG is added into the dry dairy cow TMR, the postpartum daily gain of the offspring calves can be directly increased, the BAT development and heat production glycolipid metabolism functions are activated, and the glucose utilization efficiency of the body is optimized in a long-term mode.

The invention relates to actinobacillus succinogenes ZY130 (Actinobacillus succinogenes), which is characterized in that the preservation number of the actinobacillus succinogenes ZY130 is CCTCC (China Center For Type Culture Collection) NO: M 20251474. A strain for producing succinic acid is obtained from bovine rumen through primary screening and HPLC detection, it is determined that the strain belongs to actinobacillus succinogenes through molecular biological identification, the glucose utilization capacity, the xylose utilization capacity and the synchronous utilization capacity of mixed sugar of the strain are explored, corn straw hydrolysate obtained through an AAS method is used as a carbon source, and the actinobacillus succinogenes is obtained through high performance liquid chromatography. The utilization capability of the strain is researched.

The invention provides an engineering strain for synthesizing tryptophan by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second group of polynucleotides comprising at least one polynucleotide encoding an L-tryptophan synthesis pathway enzyme or / and a serine synthesis promoting enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the first group of polynucleotides, not only is the glucose utilization rate of the engineering strain improved, but also the yield of L-tryptophan is improved; meanwhile, by overexpressing or strengthening a plurality of L-tryptophan biosynthetic pathway related genes from different sources and knocking out or weakening L-tryptophan degradation pathway related genes, efficient fermentation production of the L-tryptophan is realized.

The invention relates to a feed for relieving growth inhibition and glucose metabolism disorder of culter alburnus induced by a high-starch feed and a preparation method thereof, belongs to the field of fish feeds, and particularly relates to the feed for relieving growth inhibition and glucose metabolism disorder of culter alburnus induced by the high-starch feed. The invention aims to solve the technical problems of extremely low tolerance of culter alburnus to high-starch feed, reduced weight gain rate, metabolic disorder and increased insulin resistance index at present. According to the invention, 2% of poly-beta-hydroxybutyrate is added into the feed containing 25% of corn starch, so that the growth performance of culter alburnus can be remarkably improved, and the utilization capacity of glucose is improved and insulin resistance and glucose metabolism disorder induced by high-starch feed are relieved by regulating mechanisms such as AKT / GSK3 beta pathway. The feed disclosed by the invention has the advantages of simple formula components, easily available raw materials, safety and harmlessness, is favorable for developing a novel green additive, and promotes healthy culture of culter alburnus.

The invention provides an engineering strain for synthesizing L-methionine by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second set of polynucleotides comprising at least one polynucleotide encoding an L-methionine synthesis pathway enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the ethylene glycol utilization gene, not only is the utilization rate of glucose improved, but also the yield of L-methionine is improved; meanwhile, by overexpressing or strengthening a plurality of L-methionine biosynthetic pathway related genes from different sources and knocking out or weakening L-methionine degradation pathway or transcription inhibition factor related genes, efficient fermentation production of L-methionine is realized.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The application discloses a composition with synergistic hypoglycemic effect and a preparation method and application thereof, and belongs to the field of biomedical technology. The composition is prepared from defatted soybean meal powder, pueraria powder, polygonatum sibiricum redoute powder, polygonatum odoratum (mill.) druce powder and oat bran powder as a composite substrate, inoculated with bacillus ATCC 6633 for aerobic fermentation, under the condition that the first stage fermentation liquor is not inactivated, glucose, pyridoxal phosphate and lactobacillus ATCC 367 are added, and micro-aerobic and low-oxygen fermentation is sequentially carried out, and the composition is prepared through solid-liquid separation, ultrafiltration, concentration and drying. The composition can inhibit alpha-glucosidase activity, promote glucose utilization, improve insulin resistance and increase liver glycogen content, and can be used for preparing products for treating type 2 diabetes and auxiliary regulation of blood sugar.

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention discloses a glucokinase mutant for enhancing the glucose utilization rate of escherichia coli and application of the glucokinase mutant. The invention belongs to the technical field of biology, and particularly relates to a glucokinase mutant for enhancing the glucose utilization rate of escherichia coli and application of the glucokinase mutant. The mutant protein disclosed by the invention is any one of the following proteins: 1) a protein obtained by mutating the 142 A of a sequence 1 into V or L and keeping other amino acid residues unchanged; 2) a protein obtained by mutating R in the 188th sequence of the sequence 1 into H and keeping other amino acid residues unchanged; and 3) a protein obtained by mutating the 142 of the sequence 1 into V or L, mutating R of the 188 of the sequence 1 into H and keeping other amino acid residues unchanged. The encoding gene of glucokinase in receptor escherichia coli is knocked out, and the encoding gene of mutant protein is introduced into the receptor escherichia coli, so that the enzyme activity of the obtained recombinant escherichia coli is 7.3 times that of wild escherichia coli, and the glucose utilization rate of escherichia coli is increased.

This invention relates to 1,2,5-benzothiazazacycloheptatriene derivatives of formula (I). These compounds are bile acid modulators with inhibitory activity against apical sodium-dependent bile acid transporters (ASBT) and / or hepatic bile acid transporters (LBAT). The invention also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases.

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators which have inhibitory activity on the apical sodium-dependent bile acid transporter (ASBT) and / or on hepatic bile acid transport (LBAT). The invention also relates to pharmaceutical compositions containing these compounds and to the use of these compounds in the treatment of cardiovascular diseases, disorders of fatty acid metabolism and glucose utilization, gastrointestinal diseases and liver diseases.